Select Safety Information News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Select Safety Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Select Safety Information Today - Breaking & Trending Today

CDC's ACIP Unanimously Votes to Provisionally Recommend Use of Merck's VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children Seite 1

Published: June 22, 2022

23.06.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to include VAXNEUVANCETM ... Seite 1

Source: wallstreet-online.de

CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE in Series with PNEUMOVAX ® 23 as an Option for Pneumococcal Vaccination in Appropriate Adults

Published: October 21, 2021

Series Would be Routinely Recommended Both for Adults 65 Years and Older and for Adults Ages 19 to 64 at Increased Risk for Disease, Such as Those with Certain Underlying Medical Conditions Merck known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted in favor of updates to pneumococcal ...

Source: investingnews.com

Merck Announces U.S. FDA Approval of VAXNEUVANCE for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

Published: July 17, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration approved VAXNEUVANCE ™ for active immunization for the prevention of … Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) VAXNE...